ChlVPP | Cancer information | Cancer Research UK - MeSH terms
Looking for:
ChlVPP-EVA regimen - wikidoc. |
Chlorambucil vinblastine procarbazine prednisone
SEER*Rx Interactive Antineoplastic Drugs Database.
Do not code Prednisone when it is given to treat symptom s or as a single agent. In most case s when Prednisone is given by itself and not as part of a drug regimen , it does not affect the cancer and would not be coded as treatment.
Name Vincristine. Antineoplastic ; vinca plant alkaloid ; antimetabolite. Name Vinblastine. Plant alkaloid. A cell cycle specific chemotherapeutic agent; vinca plant alkaloid ; mitotic inhibitor. Br Med J. Radiotherapy in the treatment of Hodgkin's disease. Mediastinal involvement in early-stage Hodgkin's disease. Response to treatment and pattern of relapse. Eur J Cancer.
Associated Data Supplementary Materials. Open in a separate window. Full text links Read article at publisher's site DOI : Smart citations by scite. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed. Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Current treatment of Hodgkin's disease. Is combined modality therapy necessary for advanced Hodgkin's disease? Management of Relapsed and Refractory Hodgkin's Disease. Similar Articles To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
ChlVPP chemotherapy in advanced Hodgkin's disease. Joining Europe PMC. Tools Tools overview. ORCID article claiming. Journal list. Grant finder. External links service. Annotations submission service.
Developers Developer resources. API case studies. Although an evidence-based standard is lacking for older patients with HL, most groups regard 4 cycles of ABVD in early unfavorable and 6 to 8 cycles of ABVD in advanced stages as standard of care. This is often followed by involved field radiotherapy of 30 Gy for early unfavorable and radiation to residual disease for advanced-stage patients.
It is generally accepted that antitumor activity and tolerability of ABVD in this patient cohort needs further improvement. Because chemotherapy intensification has major limitations in older patients with HL as also seen in the present study, we urgently need new approaches that include nongenotoxic drugs to be evaluated in older patients with HL.
In addition, new trials should also incorporate special geriatric assessments that might help to improve the estimate of frailty. Although this is within the range of other regimens used, we do not recommend BACOPP outside clinical trails in this patient population. The publication costs of this article were defrayed in part by page charge payment. We thank all the contributing centers. Contribution: L. For a complete list of the members of the German Hodgkin Study Group, see the supplemental Appendix available on the Blood Web site; see the Supplemental Materials link at the top of the online article.
Sign In or Create an Account. Sign In. Search Dropdown Menu. Skip Nav Destination Content Menu. Close Abstract. Article Navigation. Lymphoid Neoplasia September 23, Halbsguth , Teresa V. This Site. Google Scholar. Horst Mueller , Horst Mueller. Michal Sieniawski , Michal Sieniawski. Dennis A. Eichenauer , Dennis A. Thomas Schober , Thomas Schober. Peter Borchmann , Peter Borchmann.
Volker Diehl , Volker Diehl. Andreas Engert , Andreas Engert. Andreas Josting Andreas Josting. Blood 12 : — Article history Submitted:. Cite Icon Cite.
Table 1 Drug doses and schedules. View Large. Figure 1. View large Download PPT. Patients assessed and included for final analysis. Table 2 Patient characteristics. WHO grade, no. Anemia 9 1 17 24 41 Thrombopenia 2 11 22 16 49 Leucopenia 10 32 70 84 92 Infection 12 2 23 12 23 Nausea 5 8 12 18 Mucositis 7 12 13 Gastrointestinal tract 3 5 4 3 Respiratory 4 3 12 8 Cardiac 4 1 8 8 15 Neurotoxicity 6 1 12 12 Table 4 Treatment outcome.
You usually have ChlVPP as a course of several cycles of treatment. A cycle means that you have the drugs and then a rest to allow your body to recover. You have blood tests before and during your treatment. They check your levels of blood cells and other substances in the blood. They also check how well your liver and kidneys are working. How often and how severe the side effects are can vary from person to person. They also depend on what other treatments you're having.
For example, your side effects could be worse if you're also having other drugs or radiotherapy. Your doctor, nurse or pharmacist will go through the possible side effects. They will monitor you closely during treatment and check how you are at your appointments. Contact your advice line as soon as possible if:. We haven't listed all the side effects here. Remember it is very unlikely that you will have all of these side effects, but you might have some of them at the same time.
You might have one or more of them. They include:. Increased risk of getting an infection is due to a drop in white blood cells. Symptoms include a change in temperature, aching muscles, headaches, feeling cold and shivery and generally unwell. You might have other symptoms depending on where the infection is. Infections can sometimes be life threatening. You should contact your advice line urgently if you think you have an infection. This is due to a drop in the number of platelets in your blood.
These blood cells help the blood to clot when we cut ourselves. You may have nosebleeds or bleeding gums after brushing your teeth. Or you may have lots of tiny red spots or bruises on your arms or legs known as petechiae. You might be breathless and look pale due to a drop in red blood cells.
This is called anaemia.
❾-50%}Chlorambucil vinblastine procarbazine prednisone. ChlVPP-EVA regimen
Barrett A ,. Peckham MJ. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract Since , patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone ChlVPP. Free full text. Br J Cancer. Dady , T. McElwain , D. Austin , A. Barrett , and M. Copyright and License information Disclaimer.
Copyright notice. This article is licensed under a Creative Commons Attribution 4. This article has been cited by other articles in PMC. Aisenberg AC. The staging and treatment of Hodgkin's disease. N Engl J Med. Cancer Treat Rep. Cancer Res. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. Curability of advanced Hodgkin's disease with chemotherapy. Combination chemotherapy in advanced Hodgkin's disease.
Induction and maintenance of remission. Three years' experience with Ch1VPP a combination of drugs of low toxicity for the treatment of Hodgkin's disease. Studies on the mechanism of radiation-induced leukemogenesis in C57BL mice.
A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Combination chemotherapy in advanced and recurrent Hodgkin's disease. Natl Cancer Inst Monogr. Hodgkin's disease in children. The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination.
Cancer Treat Rev. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J. Radiotherapy in the treatment of Hodgkin's disease.
Mediastinal involvement in early-stage Hodgkin's disease. So there is a risk of developing diabetes or making your diabetes worse while on this medication. You might have regular blood and urine tests to check this. You might need to have blood sugar lowering treatment. But your sugar levels usually go back to normal shortly after you stop taking steroids. If you have diabetes already, you might need to check your blood sugar levels more often than usual.
They could make you very ill. Tell your doctor or nurse straight away if you have been with someone who has chicken pox or shingles. You may not be able to become pregnant or father a child after treatment with these drugs. Talk to your doctor before starting treatment if you think you may want to have a baby in the future. Men might be able to store sperm before starting treatment.
And women might be able to store eggs or ovarian tissue. But these services are not available in every hospital, so you would need to ask your doctor about this. This treatment may harm a baby developing in the womb. It is important not to become pregnant or father a child while you are having treatment with this drug and for at least a year afterwards. Talk to your doctor or nurse about effective contraception before starting treatment.
The length of time depends on the treatment you are having. Ask your doctor or pharmacist how long you should avoid live vaccinations.
In the UK, live vaccines include rubella, mumps, measles, BCG, yellow fever and one of the shingles vaccines called Zostavax. This is to help lower your risk of getting COVID while having cancer treatment and until your immune system recovers from treatment. Contact with others who have had immunisations - You can be in contact with other people who have had live vaccines as injections. Avoid close contact with people who have recently had live vaccines taken by mouth oral vaccines such as the oral typhoid vaccine.
If your immune system is severely weakened, you should avoid contact with children who have had the flu vaccine as a nasal spray as this is a live vaccine. This is for 2 weeks following their vaccination. Babies have the live rotavirus vaccine. Get someone else to change their nappies during this time if you can. If this isn't possible, wash your hands well after changing their nappy.
For further information about this treatment go to the electronic Medicines Compendium eMC website. Cancer drugs have side effects and these can vary from person to person.
But there are things that you can do to help you cope. Hodgkin lymphoma is a cancer of a type of white blood cell called lymphocytes. Hodgkin lymphomas contain cells called Reed Sternberg cells. Treatment for Hodgkin lymphoma is different from other types of lymphoma. Chemotherapy is anti cancer drug treatment. Find out about when you might have it, how you have it and possible side effects.
Steroids are used in different ways during cancer treatment. It is generally accepted that antitumor activity and tolerability of ABVD in this patient cohort needs further improvement. Because chemotherapy intensification has major limitations in older patients with HL as also seen in the present study, we urgently need new approaches that include nongenotoxic drugs to be evaluated in older patients with HL.
In addition, new trials should also incorporate special geriatric assessments that might help to improve the estimate of frailty. Although this is within the range of other regimens used, we do not recommend BACOPP outside clinical trails in this patient population. The publication costs of this article were defrayed in part by page charge payment. We thank all the contributing centers.
Contribution: L. For a complete list of the members of the German Hodgkin Study Group, see the supplemental Appendix available on the Blood Web site; see the Supplemental Materials link at the top of the online article. Sign In or Create an Account. Sign In. Search Dropdown Menu. Skip Nav Destination Content Menu.
Close Abstract. Article Navigation. Lymphoid Neoplasia September 23, Halbsguth , Teresa V. This Site. Google Scholar. Horst Mueller , Horst Mueller. Michal Sieniawski , Michal Sieniawski. Dennis A. Eichenauer , Dennis A. Thomas Schober , Thomas Schober. Peter Borchmann , Peter Borchmann.
Volker Diehl , Volker Diehl. Andreas Engert , Andreas Engert. Andreas Josting Andreas Josting. Blood 12 : — Article history Submitted:. Cite Icon Cite. Table 1 Drug doses and schedules. View Large. Figure 1. View large Download PPT. Patients assessed and included for final analysis. Table 2 Patient characteristics. WHO grade, no.
Anemia 9 1 17 24 41 Thrombopenia 2 11 22 16 49 Leucopenia 10 32 70 84 92 Infection 12 2 23 12 23 Nausea 5 8 12 18 Mucositis 7 12 13 Gastrointestinal tract 3 5 4 3 Respiratory 4 3 12 8 Cardiac 4 1 8 8 15 Neurotoxicity 6 1 12 12 Table 4 Treatment outcome. CR indicates complete remission; and CRu, complete remission uncertain with residual lesion.
Table 5 Causes of death. HD9 elderly. Hodgkin lymphoma 6 10 23 17 Acute toxicity 7 12 8 21 Second malignancy 2 3 8 10 Other 3 5 15 7 Total deaths 18 30 54 55 Median observation time, mo 33 Figure 2.
The online version of this article contains a data supplement. Conflict-of-interest disclosure: The authors declare no competing financial interests.
Search ADS. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Survival of the older patient compared with the younger patient with Hodgkin's disease.
Influence of histologic type, staging, and treatment. Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E. A prognostic score for advanced Hodgkin's disease. Clinical data and therapeutic approach in elderly patients with Hodgkin's disease. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma,
Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page. Sincepatients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone ChlVPP.
ChlVPP has few side effects, is easily given to outpatients, and can be combined with elective radiotherapy in selected patients. Read article at publisher's site DOI : Molin D. Ups J Med Sci301 Jan Cited by: 14 articles PMID: Crit Rev Oncol Hematol35 101 Jul Cited by: 3 articles PMID: Cowen D. Cancer Radiother3 201 Mar Cited by: 0 articles PMID: Cited by: 1 article PMID: Yahalom J. Semin Radiat Oncol6 301 Jul Cited by: 5 articles PMID: To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Br J Cancer36 201 Aug Br J Cancer39 201 Feb Cited by: 8 articles PMID: Vose JM. Leuk Lymphoma15 Suppl01 Jan Cited by: 2 articles PMID: Canellos GP. Semin Oncol17 1 suppl 201 Feb Contact us. Europe PMC requires Javascript to function effectively.
Recent Activity. Search life-sciences literature 41, articles, preprints and more Search Advanced search. This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.
Dady PJ. McElwain TJ. Austin DE. A Barrett Search articles by 'A Barrett'. Barrett A. Peckham MJ. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract Sincepatients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone ChlVPP. Free full text. Br J Cancer. DadyT. McElwainD. AustinA. Barrettand M.
Copyright and License information Disclaimer. Copyright notice. This article is licensed under a Creative Commons Attribution 4. This article has been cited by other articles in PMC. Aisenberg AC. The staging and treatment of Hodgkin's disease. N Engl J Med. Cancer Treat Rep. Cancer Res.
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. Curability of advanced Hodgkin's disease with chemotherapy. Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. Three years' experience with Ch1VPP a combination of drugs of low toxicity for the treatment of Hodgkin's disease. Studies on the mechanism of radiation-induced leukemogenesis in C57BL mice.
A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Combination chemotherapy in advanced and recurrent Hodgkin's disease. Natl Cancer Inst Monogr. Hodgkin's disease in children. The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination.
Cancer Treat Rev. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J. Radiotherapy in the treatment of Hodgkin's disease. Mediastinal involvement in early-stage Hodgkin's disease. Response to treatment and pattern of relapse. Eur J Cancer. Associated Data Supplementary Materials. Open in a separate window. Full text links Read article at publisher's site DOI : Smart citations by scite. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed. Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Current treatment of Hodgkin's disease. Is combined modality therapy necessary for advanced Hodgkin's disease?
Management of Relapsed and Refractory Hodgkin's Disease. Similar Articles To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation. ChlVPP chemotherapy in advanced Hodgkin's disease. Joining Europe PMC. Tools Tools overview. ORCID article claiming. Journal list. Grant finder. External links service. Annotations submission service.
Developers Developer resources. API case studies. SOAP web service. Annotations API. OAI service.
Abstract. Seventy patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP). Chlorambucil is available as 2 mg tablets. Procarbazine is available as 50 mg capsules. Prednisolone is available as 25 mg, 5 mg and 1 mg tablets. The toxicity of MOPP chemotherapy, including nausea, vomiting, hair loss, and neuropathy, can limit patient compliance. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer, 36 (), p. COPP (cyclophosphamide, vincristine, procarbazine, and prednisone) or ChlVPP (chlorambucil, vinblastine, procarbazine, and prednisone). For a complete list of the members of the German Hodgkin Study Group, see the supplemental Appendix available on the Blood Web site; see the Supplemental Materials link at the top of the online article. This can be a:. It includes content provided to the PMC International archive by participating publishers. Steroids are used in different ways during cancer treatment. Thank you for submitting a comment on this article.Teresa V. Blood ; 12 : — For older patients with early unfavorable or advanced stage Hodgkin lymphoma HL the prognosis is much worse than for younger HL patients.
We thus developed a new regimen, BACOPP bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone , to improve both tolerability and efficacy of treatment for older HL patients. Between and , 65 patients with early unfavorable or advanced stage HL aged between 60 and 75 years were enrolled in this phase 2 trial.
Residual tumor masses were irradiated. Primary endpoints were feasibility as determined by adherence to protocol and overall response rate. Secondary endpoints included toxicity, freedom from treatment failure, and progression free and overall survival. Three patients died before response assessment. This trial was registered at www. During the past 3 decades the prognosis for patients with Hodgkin Lymphoma HL has substantially improved.
This success is mainly based on the introduction of effective combination chemotherapy regimens, progress in radiation techniques, and constant optimization of treatment methods. Unfortunately, these improvements have not been extended to older patients despite some better understanding of the pathophysiology.
Anthracyclines might be one of the most relevant components of chemotherapy in older patients. Patients with impaired heart, lung, liver, or kidney function; deficiency of vitamin B 12 or folic acid; hemolysis; previous malignant disease; positive HIV status; or hepatitis B infection were not included.
Biopsy material was judged by the local pathologist and then reviewed by at least 1 member of the central pathology review panel consisting of 6 German HL experts.
Composite lymphomas were excluded. Staging and pretreatment evaluation contained medical history; physical examination; chest radiography; computed tomography of the neck, chest, abdomen, and pelvis; ultrasound scans of the neck and the abdomen; bone marrow biopsy; skeletal scintigraphy; serum chemistry; lung function test; electrocardiography; and echocardiography.
Written informed consent was signed by each patient before enrollment. The study was approved by the University Hospital of Cologne Ethic Committee, conducted in accordance with the Declaration of Helsinki, and registered at www. A routine safety monitoring was conducted throughout the whole study. All cytotoxic drugs were given within 8 days and recycled after 21 days. For patients older than 65 years the vincristine dose was restricted to 1 mg.
The regimen is shown in Table 1. Patients achieving a complete remission CR after 4 cycles of BACOPP received 2 additional cycles of treatment, whereas patients with a partial remission PR were to receive 4 additional cycles. Patients younger than 65 years receive a maximum of 2 mg; patients older than 65 years receive a maximum of 1 mg.
Radiation fields were restricted to the residual mass and irradiated with 30 Gy. Radiotherapy was also used to treat osteolytic bone lesions. All toxicities determined under therapy and during follow-up had to be documented according to the WHO toxicity criteria. The final restaging was performed in the last week of chemotherapy or in the case of additional radiotherapy 4 to 6 weeks after the end of irradiation and included assessment of initial involved sites.
Residual disease after chemotherapy and radiotherapy was considered as CRu CR uncertain with residual lesion when no additional treatment was required.
Feasibility was measured according to protocol adherence. A vincristine dose of 2 mg in patients older than 65 years was no protocol deviation. Between January and December , a total of 65 patients were registered.
Five patients had to be excluded, 2 with no HL and 1 each for wrong staging, previous treatment, or withdrawn consent. Thus, 60 patients were eligible for the final analysis Figure 1. Median age was Of 60 patients, 45 received their treatment according to protocol. Reasons for early termination were extensive toxicity 9 patients , concomitant disease 4 patients , patients wish 2 patients , progression 1 patient , and others 2 patients.
Radiotherapy according to protocol was performed in 8 patients. For cycles 2 to 6 the number of days with G-CSF ranged between 1 day and 14 days mean: 4. In cycle 7 and 8 the mean was 5. There was no statistically significant difference in the proportion of severe infections or sepsis between patients receiving G-CSF and those who never were treated with G-CSF.
According to treatment arm, 14 patients treated with 6 cycles of BACOPP were nonresponders with a red blood cell transfusion given in 7 patients. In the group of patients who received 8 cycles of BACOPP, 15 patients were classified as nonresponders with a need of red blood cell transfusions in 5 patients.
No thromboses or thromboembolic events have been registered throughout the study and follow-up period. Deaths from acute toxicity occurred in 7 patients 2 women and 5 men because of severe infection after 1. The subgroup analysis showed no association between the development of toxicity and IPS or stage.
Five percent died before restaging with unknown response Table 4. With a median observation time of 33 months, a total of 8 relapses and 5 second malignancies 3 patients with non-Hodgkin lymphoma NHL , 2 with lung cancer were observed. In the follow-up, 6 patients died of relapsing or progressing HL, 2 of second malignancies 1 of lung cancer after 44 months and 1 of secondary B-cell NHL after 17 months and 3 patients as a result of other reasons.
The causes of death are listed in Table 5. C Kaplan-Meier analysis of overall survival OS. Primary progressive disease was observed in 4 patients. Early termination of therapy because of toxicity became necessary in 1 patient with progressive disease. The other 3 patients died within 6. All 3 patients had received salvage chemotherapy.
In 1 case additional radiation was given. Relapse after the end of therapy was documented in 8 patients occurring 8 to 28 months after registration. Three patients died within 5 months after diagnosis of relapse, 1 because of second malignancy. Salvage chemotherapy was given in 2 of these patients.
Five patients alive at the time of this analysis received salvage radiotherapy 2 patients or salvage chemotherapy 2 patients ; 1 patient refused salvage therapy. A complete remission was achieved only in 1 patient treated with salvage radiation. The other patients progressed or relapsed after salvage therapy.
All these patients were under treatment at the time of the present analysis. The primary objective of this phase 2 trial was feasibility and efficacy of the newly developed BACOPP regimen for older patients with HL in early unfavorable and advanced stages.
The following findings emerge from this study. This response is among the best reported so far in older patients with HL. Older patients with HL generally have a poorer prognosis than patients younger than 60 years.
The outcome was not associated with stage or IPS, although these results might be humbled by the small sample size. There was also no association of these events with stage or IPS. Information on toxic deaths after ABVD are however scarce, particularly in older patients. Of those patients, 2 died of toxicity. G-CSF has been suggested to reduce the incidence of severe neutropenia and toxic death in cancer patients undergoing chemotherapy. It thus remains to be shown if the routine use of G-CSF improves the survival in older patients with HL undergoing chemotherapy.
The pilot study raised expectations that it might be both effective and well tolerated. However, the patient numbers are too small for further conclusions. In older patients with HL, historical comparison of efficacy and tolerability between trials are generally more difficult because of the small patient numbers and different patient characteristics.
Patients included in the prior randomized GHSG HD9elderly study were older than those in the present trial median age of Although an evidence-based standard is lacking for older patients with HL, most groups regard 4 cycles of ABVD in early unfavorable and 6 to 8 cycles of ABVD in advanced stages as standard of care. This is often followed by involved field radiotherapy of 30 Gy for early unfavorable and radiation to residual disease for advanced-stage patients.
It is generally accepted that antitumor activity and tolerability of ABVD in this patient cohort needs further improvement. Because chemotherapy intensification has major limitations in older patients with HL as also seen in the present study, we urgently need new approaches that include nongenotoxic drugs to be evaluated in older patients with HL.
In addition, new trials should also incorporate special geriatric assessments that might help to improve the estimate of frailty. Although this is within the range of other regimens used, we do not recommend BACOPP outside clinical trails in this patient population. The publication costs of this article were defrayed in part by page charge payment. We thank all the contributing centers. Contribution: L. For a complete list of the members of the German Hodgkin Study Group, see the supplemental Appendix available on the Blood Web site; see the Supplemental Materials link at the top of the online article.
Sign In or Create an Account. Sign In. Search Dropdown Menu. Skip Nav Destination Content Menu. Close Abstract. Article Navigation. Lymphoid Neoplasia September 23, Halbsguth , Teresa V. This Site. Google Scholar.
Comments
Post a Comment